Bookmark

Add to MyYahoo RSS

MannKind News

News on MannKind (Ticker: MNKD) continually updated from thousands of sources around the net.

Friday Jul 25 | Seeking Alpha

MannKind: Why The Short Argument Is Shortsighted

Behavioral finance theory tells us that one should not underestimate the influence of the patient population and their families in the potential success of MannKind's Afrezza.

Comment?

Related Topix: Biotech, Valencia, CA

Thu Jul 24, 2014

GuruFocus.com

MannKind Corporation: Investors Should Seek Truth As The Requisite To Finding This Alpha

Despite MannKind's positive developments including the company's stellar Affinity Trials' data, unanimous backing from Advisory Committees experts, and FDA approval for Afrezza, Mr. Market's persistent condemnation of MannKind continues.

Comment?

Related Topix: Biotech, Healthcare Law, Law, Valencia, CA, Medicine, Diabetes, Health, Science / Technology

Insider Monkey

Jason Karp Hates MannKind Corporation (MNKD), Likes NCR Corporation,...

According to CNBC , Tourbillon Capital's Jason Karp is betting on a decline of MannKind Corporation shares.

Comment?

Related Topix: Computers, NCR, Biotech, Ctrip.com International

Wed Jul 23, 2014

Seeking Alpha

AFREZZA Is A Brilliant Technology Without A Compelling Marketing Story

The issue of lung safety and lung cancer with inhaled insulin has not gone away, and should not be underestimated.

Comment?

Related Topix: Health, Lung Cancer, Marketing, Medicine, Insulin (generic), Humulin, Novolin, Diabetes, Biotech, Food and Drug Administration

Mon Jul 21, 2014

Seeking Alpha

5 More Possible Partners For MannKind's Afrezza, Each With A Strong Diabetes Care Franchise

However, in all but one case, Afrezza may compete with their strongest and most profitable existing drug or with new drugs in their pipelines.

Comment?

Related Topix: Diabetes, Health, Biotech, Marketing, Insulin (generic), Humulin, Novolin, Sales

Sat Jul 19, 2014

GuruFocus.com

Recent Tsunami of Insider Shares Purchased: A Prelude To Mannkind Partnership or Acquisition

The prior day's massive insider shares purchased lend support to investor's sentiment that Mannkind would finalize potential buyout or partnership negotiation soon, and this would unlock significant value for shareholders.

Comment?

Related Topix: Biotech, Marketing, Sales, Medicine, Diabetes, Health, Insulin (generic), Humulin, Novolin, Valencia, CA

Thu Jul 17, 2014

AmericanBankingNews.com

Insider Selling: Diane Palumbo Unloads 17,901 Shares of MannKind Stock

MannKind VP Diane Palumbo unloaded 17,901 shares of the stock in a transaction that occurred on Tuesday, July 15th.

Comment?

Related Topix: Biotech

AmericanBankingNews.com

MannKind Trading Down 3.4% After Insider Selling

MannKind fell 3.4% on Thursday after an insider sold shares in the company, Analyst Ratings Net reports.

Comment?

Related Topix: Biotech

SchaeffersResearch.com

Most Active Options Update: Micron Technology, Inc.

The 20 stocks listed in the table below have attracted the highest total options volume during the past 10 trading days.

Comment?

Related Topix: Semiconductors, Micron Technology, Electronics, Financial Markets, Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, Banking, JP Morgan Chase

Wed Jul 16, 2014

GuruFocus.com

Mannkind Corporation: Why Afrezza Would Completely Dominate The Insulin Market

Mannkind Corporation is a small company based in Valencia, California, focusing on the development and commercialization of medicine to treat diabetes.

Comment?

Related Topix: Medicine, Insulin (generic), Humulin, Novolin, Biotech, Valencia, CA

Seeking Alpha

AntriaBio Presents Vast Upside With Disruptive Once-Weekly Insulin

AntriaBio's once-weekly insulin injection is in early-stage development, but as the examples used have shown, potentially disruptive drugs candidates have warranted rich valuations even at early stages.

Comment?

Related Topix: Biotech, Food and Drug Administration, Marketing, Novo Nordisk AS

Mon Jul 14, 2014

Seeking Alpha

MannKind: Are These Top Big Pharma Companies Potential Partners?

The ideal partner would be a large, global company with a strong presence in the diabetes care niche but with no product whose sales would be threatened by a successful Afrezza.

Comment?

Related Topix: Biotech, Medicine, Diabetes, Health, Insulin (generic), Humulin, Novolin, Food and Drug Administration, Sales, Marketing

Fri Jul 11, 2014

The Motley Fool

Is This MannKind's Greatest Risk?

Instead, those predictions swung and missed. The U.S. Food and Drug Administration recently approved the inhaled insulin.

Comment?

Related Topix: Biotech, Food and Drug Administration, Medicine, Insulin (generic), Humulin, Novolin, Diabetes, Health, Marketing

Fri Jul 04, 2014

The Motley Fool

3 Things to Look for in MannKind's Partnership

What's taking so long? I jest. But I'm allowed to. MannKind has been talking about a partnership since before the FDA first rejected the drug f Without a doubt, a partnership is the next big catalyst for the stock now that Afrezza is approved.

Comment?

Related Topix: Biotech, Food and Drug Administration, Medicine, Insulin (generic), Humulin, Novolin, Marketing, Diabetes, Health, Sales

Diabetes Self Management

FDA Approves Inhalable Insulin

On June 27, the US Food and Drug Administration approved Afrezza, a first-in-class inhalable insulin/inhaler combination, for adults with diabetes.

Comment?

Related Topix: Medicine, Insulin (generic), Humulin, Novolin, Healthcare Law, Law, Food and Drug Administration, Diabetes, Health, Biotech, Marketing

Thu Jul 03, 2014

AmericanBankingNews.com

MannKind CFO Matthew J. Pfeffer Sells 20,000 Shares

MannKind CFO Matthew J. Pfeffer sold 20,000 shares of the company's stock in a transaction dated Tuesday, July 1st.

Comment?

Related Topix: Biotech

Freshnews

MannKind Corp Analyst Report; Afrezza is Approved and Future...

MannKind Corporation is a biopharmaceutical company focused on the discovery and development of therapeutic products for diseases such as diabetes.

Comment?

Related Topix: Biotech, Medicine, Health, Diabetes, Insulin (generic), Humulin, Novolin

Freshnews

The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, MannKind,...

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets.

Comment?

Related Topix: Vertex, Biotech, Vertex Pharmaceuticals, Medicine, Healthcare Industry, Financial Markets, Auxilium Pharmaceuticals, QLT

Wed Jul 02, 2014

AmericanBankingNews.com

Insider Buying: Hakan Edstrom Buys 1,692 Shares of MannKind Stock

MannKind COO Hakan Edstrom purchased 1,692 shares of MannKind stock in a transaction dated Monday, June 30th.

Comment?

Related Topix: Biotech

Tue Jul 01, 2014

MedicineNet

Inhaled Insulin Afrezza: FAQ

June 30, 2014 -- Millions of people with type 1 or type 2 diabetes will have another treatment option now that the FDA has approved an inhaled insulin .

Comment?

Related Topix: Medicine, Insulin (generic), Humulin, Novolin, Diabetes, Health, Healthcare Law, Law, Food and Drug Administration, Fulton County, GA, Atlanta, GA, Biotech

•••
•••
•••
•••
•••

Ashburn Jobs

•••
•••
•••
•••